UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Tag: liver disease

The Global NASH Congress – Slide release

An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.

Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.

Read More

Lifestyle Interventions in NASH – Backbone, Therapy or Waste of Time?

The effects of lifestyle interventions as a baseline therapy for the treatment of NASH are well accepted. However, there is a high degree of frustration when it comes to recommending and implementing lifestyle changes. Large interventional studies in the field of metabolic disease are largely negative with regards to long-term outcomes.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive